Hepatitis B immunoglobulin inhibits the secretion of HBV via antigen-antibody precipitation in the multivesicular body.

Abstract

BACKGROUND AND AIMS:

Although the main action of human hepatitis B immunoglobulin (HBIG) is to neutralize hepatitis B virus surface antigen (HBsAg) in serum, HBIG is known to be localized in the cell. However, the effect of intracellularly located HBIG is poorly understood because of the low purity of conventional plasma-derived HBIG (cHBIG). We attempted to elucidate the mechanism of action of internalized HBIG using recombinant HBIG (lenvervimab).

METHODS:

We used HBsAg producing cell lines, non-HBsAg cell lines and human HBsAg-producing hepatocytes. The autophagosome lysis pathway-related proteins Rab5, calnexin, giantin, and Rab7 were used to localize HBsAg and anti-HBs-IgG in the cytoplasm using Western blotting and confocal microscopy.

RESULTS:

Intracellular anti-HBs-IgG (lenvervimab and cHBIG) transported via Fc receptor-mediated endocytosis increased the number of autophagosomes. However, there was no change in autolysis. HBsAg and anti-HBs-IgG co-localized in the multivesicular body and precipitated in the cytoplasm. HBsAg secretion into culture medium decreased after lenvervimab treatment. Simultaneously, the amount of cellular HBsAg increased in the cell lines but decreased in human hepatocytes. Furthermore, intracellular lenvervimab is not easily removed from HBsAg cell lines.

CONCLUSIONS:

Lenvervimab decreases HBsAg secretion, and HBsAg antibody precipitation in the multivesicular body may play an important role.

• Authors: Kyung Chul Yoon, Sooin Seo, Kwang-Woong Lee, Seung Cheol Oh, Min Young Park, Suk Kyun Hong, YoungRok Choi, Nam-Joon Yi, Kyung-Suk Suh
• Journal: American journal of translational research (Am J Transl Res) Vol. 15 Issue 9 Pg. 5908-5920 ( 2023) ISSN: 1943-8141 [Print] United States
• PMID: 37854220 (Publication Type: Journal Article)
• Copyright: AJTR Copyright © 2023.